Latest News
Chinese mRNA-based COVID vaccines effective in preclinical trials
Last Updated: 2022-06-12 09:15 | Xinhua
 Save  Print   E-mail
Two mRNA-based COVID-19 vaccine candidates produced by Chinese manufacturer CanSino Biologics have proven effective in preclinical trials, suggesting the potential for human tests, according to a new study published in the journal Emerging Microbes & Infections.
 
Results showed that the two vaccines, the mRNA-Beta and mRNA-Omicron, can induce high-titer neutralizing antibody levels against original and multiple SARS-CoV-2 variants, such as Beta, Delta and Omicron.
 
Two doses of mRNA-Beta could induce broad protection especially for Beta and original variants. Meanwhile, mRNA-Omicron was suggested as a booster injection in mice vaccinated with primary mRNA-Beta or Ad5-nCoV, the company's recombinant COVID-19 vaccine, to offer further protection against Omicron variant, according to the study.
 
The Chinese mRNA vaccines got clinical trial approval in April and they have entered phase-1 human trials, according to a company statement released this week.
 
Compared with traditional vaccine technologies, the mRNA technology has the advantage of a shorter development and production cycle.
 
The Chinese vaccine maker said an industrialization base of the COVID-19 mRNA vaccine was under construction in Shanghai. It will enable the annual production capacity to reach 100 million doses by the end of 2022. 

(Editor:Fu Bo)

Share to 
0
Related Articles:
BACK TO TOP
  • Sports
  • Soccer
  • Basketball
  • Tennis
  • Formula One
  • Athletics
  • Others
  • Entertainment
  • Celebrity
  • Movie & TV
  • Music
  • Theater & Arts
  • Fashion
  • Beauty Pageant
Edition:
Link:    
About CE.cn | About the Economic Daily | Contact us
Copyright 2003-2024 China Economic Net. All right reserved
Chinese mRNA-based COVID vaccines effective in preclinical trials
Source:Xinhua | 2022-06-12 09:15
Share to 
0